Tetralogic Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:TLOG)

$0.04 0.01 (29.50 %)
(As of 12/10/2017 04:00 PM ET)
Previous Close$0.04
Today's Range$0.03 - $0.04
52-Week Range$0.01 - $0.16
Volume85,440 shs
Average Volume37,019 shs
Market Capitalization$1.07 million
P/E RatioN/A
Dividend YieldN/A
Beta2.82

About Tetralogic Pharmaceuticals (OTCMKTS:TLOG)

Tetralogic Pharmaceuticals logoTetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive TLOG News and Ratings via Email

Sign-up to receive the latest news and ratings for TLOG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:TLOG
CUSIPN/A
Phone610-889-9900

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.24) per share
Price / Book-0.18

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares24,470,000

Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Frequently Asked Questions

What is Tetralogic Pharmaceuticals' stock symbol?

Tetralogic Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TLOG."

How were Tetralogic Pharmaceuticals' earnings last quarter?

Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) posted its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.14. View Tetralogic Pharmaceuticals' Earnings History.

When will Tetralogic Pharmaceuticals make its next earnings announcement?

Tetralogic Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, December, 14th 2017. View Earnings Estimates for Tetralogic Pharmaceuticals.

Who are some of Tetralogic Pharmaceuticals' key competitors?

Who are Tetralogic Pharmaceuticals' key executives?

Tetralogic Pharmaceuticals' management team includes the folowing people:

  • Andrew L. Pecora M.D., Independent Chairman of the Board

How do I buy Tetralogic Pharmaceuticals stock?

Shares of Tetralogic Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tetralogic Pharmaceuticals' stock price today?

One share of Tetralogic Pharmaceuticals stock can currently be purchased for approximately $0.04.

How big of a company is Tetralogic Pharmaceuticals?

Tetralogic Pharmaceuticals has a market capitalization of $1.07 million. The biopharmaceutical company earns $-49,720,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How can I contact Tetralogic Pharmaceuticals?

Tetralogic Pharmaceuticals' mailing address is 343 PHOENIXVILLE PIKE, MALVERN PA, 19355. The biopharmaceutical company can be reached via phone at 610-889-9900 or via email at [email protected]


MarketBeat Community Rating for Tetralogic Pharmaceuticals (TLOG)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  96
MarketBeat's community ratings are surveys of what our community members think about Tetralogic Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ABuy
Consensus Rating Score: N/AN/AN/A3.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$1.00
Price Target Upside: N/AN/AN/A41.18% downside

Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Consensus Price Target History

Price Target History for Tetralogic Pharmaceuticals (OTCMKTS:TLOG)

Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/7/2016Roth CapitalLower Price TargetBuy$5.00 -> $1.00View Rating Details
(Data available from 12/10/2015 forward)

Earnings

Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Earnings History and Estimates Chart

Earnings by Quarter for Tetralogic Pharmaceuticals (OTCMKTS:TLOG)

Tetralogic Pharmaceuticals (OTCMKTS TLOG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/14/2017        
2/26/2015Q414($0.39)($0.53)$1.13 millionViewN/AView Earnings Details
11/5/2014Q314($4.34)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Tetralogic Pharmaceuticals (OTCMKTS:TLOG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Tetralogic Pharmaceuticals (OTCMKTS TLOG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.40%
Institutional Ownership Percentage: 0.02%
Insider Trades by Quarter for Tetralogic Pharmaceuticals (OTCMKTS:TLOG)

Tetralogic Pharmaceuticals (OTCMKTS TLOG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/9/2016Lifesciences Ii L.P. ClarusMajor ShareholderSell333,630$0.17$56,717.10View SEC Filing  
2/5/2016Lifesciences Ii L.P. ClarusMajor ShareholderSell1,415,490$0.18$254,788.20View SEC Filing  
2/2/2016Lifesciences Ii L.P. ClarusMajor ShareholderSell369,132$0.19$70,135.08View SEC Filing  
1/28/2016Lifesciences Ii L.P. ClarusMajor ShareholderSell311,930$0.28$87,340.40View SEC Filing  
7/10/2015Andrew L PecoraDirectorBuy50,000$2.68$134,000.00View SEC Filing  
7/9/2015Andrew L PecoraDirectorBuy50,000$2.40$120,000.00View SEC Filing  
7/2/2015Paul J SchmittDirectorBuy10,000$2.34$23,400.00View SEC Filing  
3/27/2015Pete A MeyersCFOBuy5,000$4.35$21,750.00View SEC Filing  
3/26/2015J Kevin BuchiCEOBuy5,000$4.23$21,150.00View SEC Filing  
1/7/2015J Kevin BuchiCEOBuy5,000$5.04$25,200.00View SEC Filing  
12/10/2014Colin Glenn BegleySVPBuy5,900$6.16$36,344.00View SEC Filing  
12/9/2014J Kevin BuchiCEOBuy5,000$6.01$30,050.00View SEC Filing  
12/4/2014Pete A MeyersCFOBuy1,034$4.94$5,107.96View SEC Filing  
12/2/2014J Kevin BuchiCEOBuy10,000$4.99$49,900.00View SEC Filing  
11/26/2014Colin Glenn BegleySVPBuy3,100$4.86$15,066.00View SEC Filing  
11/26/2014Lesley RussellCOOBuy20,000$4.90$98,000.00View SEC Filing  
11/25/2014Colin Glenn BegleySVPBuy2,000$4.85$9,700.00View SEC Filing  
11/18/2014J Kevin BuchiCEOBuy10,000$4.82$48,200.00View SEC Filing  
11/17/2014Andrew L PecoraDirectorBuy20,000$4.53$90,600.00View SEC Filing  
11/12/2014Peter A MeyersCFOBuy5,000$3.98$19,900.00View SEC Filing  
11/11/2014J Kevin BuchiCEOBuy10,000$3.93$39,300.00View SEC Filing  
11/10/2014Paul J SchmittDirectorBuy20,000$4.10$82,000.00View SEC Filing  
12/17/2013J Kevin BuchiCEOBuy285,714$7.00$1,999,998.00View SEC Filing  
12/17/2013James N WoodyDirectorBuy261,427$7.00$1,829,989.00View SEC Filing  
12/17/2013Peter A MeyersCFOBuy142,857$7.00$999,999.00View SEC Filing  
12/17/2013Ventures Vii Lp HealthcareMajor ShareholderBuy713,463$7.00$4,994,241.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tetralogic Pharmaceuticals (OTCMKTS TLOG) News Headlines

Source:
DateHeadline
Jazz Pharmaceuticals (JAZZ) & TetraLogic Pharmaceuticals (TLOG) Head to Head ReviewJazz Pharmaceuticals (JAZZ) & TetraLogic Pharmaceuticals (TLOG) Head to Head Review
www.americanbankingnews.com - November 27 at 1:38 AM
Reviewing XOMA Corporation (XOMA) and TetraLogic Pharmaceuticals Corporation (TLOG)Reviewing XOMA Corporation (XOMA) and TetraLogic Pharmaceuticals Corporation (TLOG)
www.americanbankingnews.com - November 17 at 3:06 AM

SEC Filings

Tetralogic Pharmaceuticals (OTCMKTS:TLOG) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Tetralogic Pharmaceuticals (OTCMKTS:TLOG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tetralogic Pharmaceuticals (OTCMKTS TLOG) Stock Chart for Sunday, December, 10, 2017

Loading chart…

This page was last updated on 12/10/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.